Vaccine research has increasingly focused on virus-like particles (VLPs) due to their unique ability to mimic the structures of viruses without containing ...

In the Virus-Like Particle Translational Oncology Laboratory, Qizhi Cathy Yao, M.D., Ph.D. is developing non-infectious HIV virus-like particles (VLPs) as candidate HIV mucosal vaccines for both ...

The formation of VLP is depicted in Figure 1. Figure 1. The formation of a virus-like particle (VLP). Image Credit: Sino Biological Inc. To enable targeted drug research, Sino Biological has ...

ProBioGen has expanded its protein and viral vector manufacturing capabilities at its Berlin headquarters, reinforcing its ...

that compared the safety and immunogenicity of a single intramuscular dose of Vimkunya (n=2559), a virus-like particle chikungunya vaccine, with placebo (n=424) in healthy participants 12 to 64 ...

The European Commission (EC) has authorised the marketing of Bavarian Nordic's Vimkunya - the first chikungunya vaccine ...

Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million.Two new early-stage pipeline ...